who invented glp 1 drugs GLP-1s and the Unintended Consequences of the $100 Billion Market Evolution of GLP‐1 Receptor Agonists

W.KnowlesJ

1985;17(8):418-421 Pijl H, Langendonk JG, Burggraaf J, et al

This activation triggers downstream signaling cascades involving TANK-binding kinase 1 (TBK1) and Interferon Regulatory Factor 3 (IRF3), ultimately driving the transcription of type I interferons (IFNs) and other antiviral effector genes

Evidence for CAT gene being functionally involved in the susceptibility of COVID-19

The human evidence is still developing

The secondary outcomes were improvement in the components of metabolic syndrome, lipid panel (total cholesterol, triglyceride, high-density lipoprotein, and low-density lipoprotein), hepatic panel (albumin, total protein, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), and adiposity, oxidative stress, and inflammation biomarkers